DOSIS OCTREOTIDE PDF

Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.

Author: Domuro JoJomuro
Country: Singapore
Language: English (Spanish)
Genre: Health and Food
Published (Last): 11 September 2015
Pages: 162
PDF File Size: 6.31 Mb
ePub File Size: 17.60 Mb
ISBN: 719-1-57639-230-9
Downloads: 59753
Price: Free* [*Free Regsitration Required]
Uploader: Zuluzshura

In non-diabetics and type II diabetics with partially intact insulin reserves, Sandostatin administration can result in post-prandial increases in glycaemia. Cardiovascular related events Common cases of bradycardia have been reported. Monitor thyroid function, gallbladder, glucose, vitamin B Maintenance doses have to be adjusted individually. Hepatic function should be monitored octreltide octreotide therapy.

Octreotide has no or negligible influence on the ability to drive and use machines. This non-specific tissue reaction appeared to be particular to rats. Clinical improvement and symptomatic benefit occur in patients octreotjde still have symptoms related to their tumours despite previous therapies, which may include surgery, hepatic artery embolization, and various chemotherapies, e.

The only adverse event reported was mild hyperglycaemia. Post-prandial glucose tolerance may be impaired and, in some instances, the state of persistent hyperglycaemia may be induced as a result of chronic administration. This is accompanied by an improvement in associated electrolyte abnormalities, e.

IGF-I somatomedin C levels every 2 weeks can be used to guide titration. Concomitant administration of octreotide and bromocriptine increases the bioavailability of bromocriptine. Step 7 After the saturation period, ensure plunger is pushed all the way down in the syringe Keep plunger pressed and shake vial moderately in a horizontal direction for a minimum of 30 seconds so the powder is completely suspended uniform milky suspension.

To email a medicine you must sign up and log in.

Skin and subcutaneous tissue disorders Common: Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis. Animal studies have shown excretion of octreotide in breast milk. Octreotide acetate 50mcg, mcg, mcg; per vial; soln for IV or SC inj; contains mannitol, phenol. Generic Name and Formulations: All the information available at present indicates that the findings in rats are species specific and have no significance for the use of the drug in humans see section 5.

  LA RAZON BLINDADA ARISTIDES VARGAS PDF

Click here to read our new policy. This medicinal product must not be mixed with other medicinal products except those mentioned in section 6. In some patients, computed tomography scanning suggests a slowing or arrest of progression of the tumour, or even tumour shrinkage, particularly of hepatic metastases. For intravenous infusion the product must be diluted prior to administration.

In most patients, the optimal daily dose will be 0. Sandostatin LAR Depot must be administered immediately after mixing. Octreotide is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.

SANDOSTATIN Dosage & Rx Info | Uses, Side Effects – MPR

Table 1 Adverse drug reactions reported in clinical studies Octreotiee disorders Very common: Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.

Date of revision of the text.

Posology Acromegaly Initially 0. Clinical improvement is usually accompanied by a reduction in plasma VIP levels, which may fall into the octrdotide reference range. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B Concomitant administration of octreotide and bromocriptine increases the bioavailability of bromocriptine.

Show table of contents Hide table of oftreotide 1. In the pre- and post-natal developmental studies, reduced growth and maturation was observed in the F1 offspring of dams given octreotide during the entire pregnancy and lactation period.

Some patients may vosis 3 or 4 weeks of such therapy. Mimics the action of naturally occuring somatostatin and decreases the secretion of gastroenterohepatic peptides that may contribute to adverse symptoms in patients with metastatic tumors, VIPomas. Diarrhea due to chemotherapy: When these occur, dksis mostly affect the skin, rarely the mouth and airways.

  ALFRESCO DEVELOPER GUIDE JEFF POTTS PDF

Sandostatin can be used in dilution with physiological saline. In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness and guarding.

Octreotide 100 micrograms/1ml Solution for Injection

Diarrhoea, abdominal pain, nausea, constipation, flatulence. In cirrhotic patients with bleeding gastro-oesophageal varices, Sandostatin has been well tolerated at continuous i. Female patients of childbearing potential should be advised to use adequate contraception if necessary during treatment with octreotide see section 4. Prior to administration the solution doeis be inspected visually for changes of colour or solid particles. Oesophageal varices Since, following bleeding episodes from oesophageal varices, there is an increased risk for the development of insulin-dependent diabetes or for changes in insulin requirement in patients with pre-existing diabetes, an appropriate monitoring of blood glucose levels is mandatory.

odtreotide

Keep the vial in the outer carton in order to protect from light. Breastfeeding It is unknown whether octreotide is excreted in human breast milk.

By continuing to browse the site you are agreeing to our policy on the use of cookies. The active substance is octreotide acetate. Acromegaly unresponsive to or oxtreotide cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. Because of its inhibitory action on growth hormone, glucagon, and insulin. If evidence of tumour expansion appears, alternative procedures may be advisable.

Local discomfort may be reduced by allowing the solution to reach room temperature before injection, or by injecting a smaller volume using a more concentrated solution. Spontaneously reported adverse reactions presented in Table 2, are reported voluntarily and it is not always possible to reliably establish frequency or a causal relationship to drug exposure.